Variant · Snv
ESR1 Y537C
CI-VAR-00004814Explore in graph →NP_000116.2:p.Tyr537CysNM_000125.3:c.1610A>GClinVar 3257896 CIViC 48
Curated evidence
Evidence by cancer (5 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 38072514
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Breast Neoplasm4 | ||||||||
| ESR1 D538G OR ESR1 Y537C OR ESR1 Y537N OR ESR1 Y537S OR ESR1 E380Q OR ESR1 Mutation | Lasofoxifene | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID12934In the randomized, open-label Phase II ELAINE-1 trial (n = 103), patients with ESR1‑mutated ER⁺/HER2⁻ mBC progressing after aromatase inhibitor plus CDK4/6 inhibitor therapy received either lasofoxife… (full text at CIViC) PMID 38072514 · Goetz et al., 2023 · Open in CIViC | civic |
| ESR1 Y537C | Hormone Therapy | Predictive | D | Supports Resistance | 3 | accepted | EID244MCF7 cell lines harboring the Y537C mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy. PMID 24185512 · Toy et al., 2013 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available